Thermo Fisher Scientific Expands Gibco™ Bacto™ Portfolio with Next-Generation, Chemically Defined Media to Boost E. coli Biomanufacturing Productivity

About this update from Thermo Fisher Scientific Inc

[{"type":"text","content":"New formulations simplify microbial bioprocessing, helping innovators scale plasmid DNA and protein production with confidence","length":126,"tagName":"p","attribs":{}},{"type":"text","content":"WALTHAM, Mass., December 15, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of Gibco™ Bacto™ CD Supreme FPM Plus and Gibco™ Bacto™ CD Supreme Feed (2X), two next-generation chemically-defined formulations that expand the Gibco™ Bacto™ CD portfolio to enhance and simplify plasmid DNA and recombinant protein production using Escherichia coli (E. coli).","length":423,"tagName":"p"},{"type":"text","content":"As demand for plasmid DNA continues to surge to support expanding gene therapy and mRNA vaccine pipelines, scalable microbial production platforms have become mission-critical. Biomanufacturers developing these therapies face growing pressure to increase yields while maintaining consistency at scale. The new Gibco™ Bacto™ CD Supreme FPM Plus and Feed (2X) address these needs by simplifying E. coli bioprocessing workflows and delivering predictable, high-quality results.","length":474,"tagName":"p"},{"type":"text","content":"Engineered to deliver higher productivity, consistent performance, and flexible scalability, the new fermentation media and feed system enable biomanufacturers and CDMOs to accelerate development timelines while reducing process variability and regulatory complexity. Together, these formulations support faster plasmid DNA and protein production while maintaining consistent quality and reproducibility from early development through commercial manufacturing.","length":460,"tagName":"p"},{"type":"text","content":""The Gibco™ Bacto™ CD Supreme platform represents a major advancement in microbial bioprocessing technology," said Sara Henneman, Vice President and General Manager of Thermo Fisher Scientific’s Cell Culture and Cell Therapy business. "Unlike traditional E. coli media that rely on complex components, the new CD Supreme formulations use a chemically-defined design that removes raw material variability, enabling more predictable fermentation and simpler regulatory documentation. This launch reflects our commitment to empowering innovators developing plasmid DNA and recombinant protein therapies."","length":621,"tagName":"p"}...

More updates from Thermo Fisher Scientific Inc